<DOC>
	<DOCNO>NCT00073840</DOCNO>
	<brief_summary>The primary objective study investigate efficacy levalbuterol 90 ug ( 2 actuation , 45 ug ) versus placebo ( 2 actuation ) treatment prevention bronchoconstriction adolescent adult subject asthma , treatment administer 4 time day ( QID ) .</brief_summary>
	<brief_title>Study Levalbuterol , Racemic Albuterol Placebo Subjects Twelve Years Age Older With Asthma</brief_title>
	<detailed_description>A double-blind , randomize , placebo- active-controlled , multicenter , parallel-group trial levalbuterol subject 12 year age old asthma . Study participation include one 1-week single-blind placebo run-in 8-week , randomize , double-blind , active-treatment period four treatment group . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Inclusion Criteria Must give write informed consent ( IC ) prior participation study . For subject 12 17 year age , IC must sign parent legal guardian . Females must sign Women Childbearing Potential Addendum Be willing able comply study procedure visit schedule Male female , least 12 year age Females 1260 year age must negative serum pregnancy test Visit 1 ( V1 ) Women child bear potential must use acceptable method birth control Must document diagnosis asthma min . 6 mo . prior V1 At V1 , subject must demonstrate baseline FEV1 within &gt; 45 % &lt; 75 % predict height , age , gender , race Following abstention medication use treat asthma , subject must demonstrate &gt; 12 % reversibility airflow obstruction within 1530 min . follow inhalation 180 µg ( 2 actuation , 90 µg ea . ) racemic albuterol MDI Must stable baseline asthma use Badrenergic agonist , and/or antiasthma antiinflammatory medication , and/or OTC asthma medication least 6 mo . prior V1 Must good health exception reversible airway disease suffer chronic condition might affect respiratory function Must chest Xray diagnostic pneumonia , atelectasis , pulmonary fibrotic disease , pneumothorax , chronic obstructive pulmonary disease , etc . Must able complete diary card medical event calendar reliably daily basis demonstrate use MiniWright PEF meter Exclusion Criteria Subject expect require disallow medication Female subject pregnant lactating Subject participate investigational drug study within 30 day prior V1 , currently participate another clinical trial Schedule prevents take first daily dose study medication and/or start study visit 9AM Subject travel commitment study would interfere trial measurement compliance Subject history hospitalization asthma within 45 day prior V1 , schedule inpatient hospitalization trial Have know sensitivity levalbuterol racemic albuterol , excipients contain formulation Subject use prescription drug albuterol sulfate administration contraindicate Subject currently diagnose lifethreatening asthma Subject clinically significant abnormality may interfere metabolism excretion study drug Have history cancer ( exception : basal cell carcinoma remission ) Have hyperthyroidism , diabetes , hypertension , cardiac disease , seizure disorder well control medication may interfere successful completion protocol Have history substance drug abuse within 12 mo . precede V1 positive urine drug screen V1 Have great 10 pack year history cigarette smoking use tobacco product within 6 mo . V1 Have document history bronchopulmonary aspergillosis form allergic alveolitis Have suffer clinically significant upper low respiratory tract infection 2 week prior V1 Have clinically significant abnormal laboratory value Have clinically significant abnormal 12lead ECG may jeopardize subject 's ability complete study Subject staff member relative staff member</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>levalbuterol</keyword>
	<keyword>asthma</keyword>
	<keyword>bronchoconstriction</keyword>
	<keyword>adolescent</keyword>
	<keyword>adult</keyword>
</DOC>